Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sparsentan vs Irbesartan in Primary FSGS
2023-505494-32-00Phase 3Completed
- Sponsor
- Travere Therapeutics
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of sparsentan in focal segmental glomerulosclerosis (FSGS) (2 arms), sponsored by Travere Therapeutics. Started Oct 2018; status: completed.
02
Drugs
sparsentan
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on 2023-505494-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505494-32-00.